DRAFT landscape of COVID-19 candidate vaccines
Diagnostic antibodies and antigens for Companion Animal disease testing
● Rabbit
Diagnostic antibodies and antigens for Swine disease testing
Diagnostic antibodies and antigens for Avian disease testing
Diagnostic antibodies and antigens for Multiple animal disease testing
Diagnostic antibodies and antigens for Ruminant disease testing
● Deer
Diagnostic antibodies and antigens for infectious and non-infectious Equine/Horse disease testing
SOCAIL MEDIA
137 candidate vaccines in clinical evaluation
| ID | Vaccine platform acronym | Vaccine platform description | Type of candidate vaccine | Route of administration | Developers | Phase | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | |
| 1 | IV | Inactivated virus | CoronaVac; SARS-CoV-2 vaccine (inactivated) | IM | Sinovac Research and Development Co., Ltd | Phase 4 | NCT04383574 | NCT04754698** | NCT04456595 | NCT04756830 | |||
| Study Report | Study Protocol | NCT04747821 | |||||||||||
| NCT04352608 | NCT04508075 | NCT04775069 | |||||||||||
| NCT04551547 | NCT04582344 | ||||||||||||
| Study Report | NCT04617483 | ||||||||||||
| Study Report | NCT04651790 | ||||||||||||
| 2 | IV | Inactivated virus | Inactivated SARS-CoV-2 vaccine (Vero cell) | IM | Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products | Phase 3 | ChiCTR2000031809 | ChiCTR2000034780 | |||||
| ChiCTR2000039000 | |||||||||||||
| NCT04510207 * | |||||||||||||
| Interim Report | NCT04612972 | ||||||||||||
| 3 | IV | Inactivated virus | Inactivated SARS-CoV-2 vaccine (Vero cell) | IM | Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products | Phase 3 | ChiCTR2000032459 | NCT04560881 | |||||
| Study Report | NCT04510207* | ||||||||||||
| 4 | VVnr | Viral vector (Non-replicating) | ChAdOx1-S – (AZD1222) (Covishield) | IM | AstraZeneca + University of Oxford | Phase 4 | PACTR202005681895696 | PACTR202006922165132 | NCT04686773 | NCT04400838 | ISRCTN89951424 | NCT04760132 | |
| 2020-001072-15 | Study Report | NCT04516746 | NCT04775069 | ||||||||||
| Interim Report | ISRCTN69254139 | Study Report | NCT04540393 | ||||||||||
| NCT04568031 | Study Report | NCT04536051 | |||||||||||
| Study Report | Study Report | EUCTR2020-005226-28-DE | |||||||||||
| NCT04444674 | Study Report | ||||||||||||
| NCT04324606 | CTRI/2020/08/027170 | Study Report | |||||||||||
| Study Report | ISRCTN69254139 | ||||||||||||
| Study Report | |||||||||||||
| Study Report | |||||||||||||
| NCT04684446 | |||||||||||||
| ISRCTN15638344 | |||||||||||||
| NCT04760730 | |||||||||||||
| 5 | VVnr | Viral vector (Non-replicating) | Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) | IM | CanSino Biological Inc./Beijing Institute of Biotechnology | Phase 3 | ChiCTR2000030906 | ChiCTR2000031781 | NCT04526990 | ||||
| NCT04313127 | NCT04398147 | NCT04566770 | NCT04540419 | ||||||||||
| NCT04568811 | NCT04341389 | ||||||||||||
| NCT04552366 | |||||||||||||
| Study Report | Study Report | ||||||||||||
| 6 | VVnr | Viral vector (Non-replicating) | Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S) | IM | Gamaleya Research Institute ; Health Ministry of the Russian Federation | Phase 3 | NCT04436471 | NCT04530396 | |||||
| Study Report | |||||||||||||
| NCT04437875 | NCT04564716 | ||||||||||||
| NCT04713488 | NCT04587219 | NCT04642339 | |||||||||||
| Study Report | NCT04640233 | NCT04656613 | |||||||||||
| NCT04760730 | NCT04741061 | ||||||||||||
| 7 | VVnr | Viral vector (Non-replicating) | Ad26.COV2.S | IM | Janssen Pharmaceutical | Phase 3 | NCT04509947 | NCT04436276 | EUCTR2020-002584-63-DE | NCT04505722 | |||
| Study Report | NCT04535453 | Study Report | |||||||||||
| Study Report | NCT04765384 | NCT04614948 | |||||||||||
| 8 | PS | Protein subunit | SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M) | IM | Novavax | Phase 3 | NCT04368988 | NCT04533399 | NCT04611802 | ||||
| Study Report | EUCTR2020-004123-16-GB | ||||||||||||
| Study Report | NCT04583995 | ||||||||||||
| 9 | RNA | RNA based vaccine | mRNA -1273 | IM | Moderna + National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 | NCT04283461 | NCT04677660 | NCT04405076 | NCT04649151 | NCT04470427 | NCT04760132 | |
| Interim Report | NCT04712110 | Study Report | Study Report | ||||||||||
| Study Report | NCT04761822 | ||||||||||||
| 10 | RNA | RNA based vaccine | BNT162 (3 LNP-mRNAs ) | IM | Pfizer/BioNTech + Fosun Pharma | Phase 4 | NCT04523571 | 2020-001038-36 | NCT04649021 | NCT04754594 | NCT04368728 | NCT04760132 | |
| Study Report | NCT04588480 | NCT04761822 | Study Report | EUCTR2021-000412-28-BE | |||||||||
| ChiCTR2000034825 | NCT04380701 | Study Report | EUCTR2021-000412-28-BE | ||||||||||
| Study Report | NCT04713553 | NCT04780659 | |||||||||||
| NCT04537949 | NCT04775069 | ||||||||||||
| EUCTR2020-003267-26-DE | |||||||||||||
| Study Report | |||||||||||||
| 11 | PS | Protein subunit | Recombinant SARS-CoV-2 vaccine (CHO Cell) | IM | Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences | Phase 3 | NCT04445194 | NCT04550351 | NCT04466085 | ||||
| ChiCTR2000035691 | Study Report | NCT04646590 | |||||||||||
| NCT04636333 | |||||||||||||
| 12 | RNA | RNA based vaccine | CVnCoV Vaccine | IM | CureVac AG | Phase 3 | NCT04449276 | NCT04515147 | NCT04652102 | NCT04674189 | |||
| PER-054-20 | |||||||||||||
| 13 | IV | Inactivated virus | SARS-CoV-2 vaccine (vero cells) | IM | Institute of Medical Biology + Chinese Academy of Medical Sciences | Phase 3 | NCT04470609 | NCT04659239 | |||||
| NCT04412538 | |||||||||||||
| Study Report | |||||||||||||
| 14 | IV | Inactivated virus | QazCovid-in® – COVID-19 inactivated vaccine | IM | Research Institute for Biological Safety Problems, Rep of Kazakhstan | Phase 3 | NCT04530357 | NCT04691908 | |||||
| 15 | DNA | DNA based vaccine | INO-4800+electroporation | ID | Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., Ltd | Phase 2/3 | NCT04336410 | NCT04447781 | ChiCTR2000040146 | NCT04642638 | |||
| Study Report | |||||||||||||
| ChiCTR2000038152 | |||||||||||||
| 16 | DNA | DNA based vaccine | AG0301-COVID19 | IM | AnGes + Takara Bio + Osaka University | Phase 2/3 | NCT04463472 | NCT04655625 | |||||
| NCT04527081 | |||||||||||||
| jRCT2051200085 | |||||||||||||
| 17 | DNA | DNA based vaccine | nCov vaccine | ID | Zydus Cadila | Phase 3 | CTRI/2020/07/026352 | CTRI/2020/07/026352 | |||||
| 18 | DNA | DNA based vaccine | GX-19 | IM | Genexine Consortium | Phase 1/2 | NCT04445389 | ||||||
| NCT04715997 | |||||||||||||
| 19 | IV | Inactivated virus | Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) | IM | Bharat Biotech International Limited | Phase 3 | NCT04471519 | NCT04641481; CTRI/2020/11/028976 | |||||
| Interim Study Report | |||||||||||||
| Study Report | |||||||||||||
| Study Report | |||||||||||||
| CTRI/2020/07/026300 | |||||||||||||
| CTRI/2020/09/027674 | |||||||||||||
| 20 | PS | Protein subunit | KBP-COVID-19 (RBD-based) | IM | Kentucky Bioprocessing Inc. | Phase 1/2 | NCT04473690 | ||||||
| 21 | PS | Protein subunit | VAT00002: SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (S protein (baculovirus production) | IM | Sanofi Pasteur + GSK | Phase 3 | NCT04537208 | NCT04762680 | PACTR202011523101903** | ||||
| 22 | RNA | RNA based vaccine | ARCT-021 | IM | Arcturus Therapeutics | Phase 2 | NCT04480957 | NCT04668339 | |||||
| NCT04728347 | |||||||||||||
| 23 | VLP | Virus like particle | RBD SARS-CoV-2 HBsAg VLP vaccine | IM | Serum Institute of India + Accelagen Pty + SpyBiotech | Phase 1/2 | ACTRN12620000817943 | ||||||
| ACTRN12620001308987 | |||||||||||||
| 24 | IV | Inactivated virus | Inactivated SARS-CoV-2 vaccine (Vero cell) | IM | Beijing Minhai Biotechnology Co | Phase 2 | NCT04758273 | NCT04756323 | |||||
| 25 | VVnr | Viral vector (Non-replicating) | GRAd-COV2 (Replication defective Simian Adenovirus (GRAd) encoding S) | IM | ReiThera + Leukocare + Univercells | Phase 2/3 | NCT04528641 | EUCTR2020-005915-39-IT | |||||
| 26 | VVnr | Viral vector (Non-replicating) | VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform | Oral | Vaxart | Phase 1 | NCT04563702 | ||||||
| 27 | VVnr | Viral vector (Non-replicating) | MVA-SARS-2-S | IM | University of Munich (Ludwig-Maximilians) | Phase 1 | NCT04569383 | ||||||
| 28 | PS | Protein subunit | SCB-2019 + AS03 or CpG 1018 adjuvant plus Alum adjuvant (Native like Trimeric subunit Spike Protein vaccine) | IM | Clover Biopharmaceuticals Inc./GSK/Dynavax | Phase 2/3 | NCT04405908 | NCT04672395 | |||||
| Study Report | |||||||||||||
| Report | |||||||||||||
| 29 | PS | Protein subunit | COVAX-19® Recombinant spike protein + adjuvant | IM | Vaxine Pty Ltd. | Phase 1 | NCT04453852 | ||||||
| Protein subunit | MF59 adjuvanted SARS-CoV-2 Sclamp vaccine | IM | CSL Ltd. + Seqirus + University of Queensland | Phase 1 | Development has been suspended and the candidate vaccine has been removed from the landscape summary analysis | ||||||||
| 30 | PS | Protein subunit | MVC-COV1901 (S-2P protein + CpG 1018) | IM | Medigen Vaccine Biologics + Dynavax + National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | NCT04487210 | NCT04695652 | |||||
| 31 | PS | Protein subunit | FINLAY-FR1 anti-SARS-CoV-2 Vaccine (RBD + adjuvant) | IM | Instituto Finlay de Vacunas | Phase 1/2 | RPCEC00000338 | RPCEC00000332 | |||||
| 32 | PS | Protein subunit | FINLAY-FR-2 anti-SARS-CoV-2 Vaccine (RBD chemically conjugated to tetanus toxoid plus adjuvant) | IM | Instituto Finlay de Vacunas | Phase 3 | RPCEC00000340 | RPCEC00000347 | RPCEC00000354 | ||||
| 33 | PS | Protein subunit | EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) | IM | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector” | Phase 3 | NCT04527575 | NCT04780035 | |||||
| 34 | PS | Protein subunit | RBD (baculovirus production expressed in Sf9 cells) Recombinant SARS-CoV-2 vaccine (Sf9 Cell) | IM | West China Hospital + Sichuan University | Phase 2 | ChiCTR2000037518 | ChiCTR2000039994 | |||||
| NCT04530656 | NCT04640402 | ||||||||||||
| NCT04718467 | |||||||||||||
| 35 | PS | Protein subunit | IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides) | SC | University Hospital Tuebingen | Phase 1 | NCT04546841 | ||||||
| 36 | PS | Protein subunit | UB-612 (Multitope peptide based S1-RBD-protein based vaccine) | IM | COVAXX + United Biomedical Inc | Phase 2/3 | NCT04545749 | NCT04773067 | NCT04683224 | ||||
| Viral vector (Replicating) | V591-001 – Measles-vector based (TMV-o38) | IM | Merck & Co. + Themis + Sharp & Dohme + Institute Pasteur + University of Pittsburgh | Phase 1/2 | NCT04497298 | CT04498247 | Development has been suspended and the candidate vaccines has been removed from the landscape summary analysis | ||||||
| NCT04569786 | |||||||||||||
| 37 | VVr | Viral vector (Replicating) | DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD ) | IN | University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy | Phase 2 | ChiCTR2000037782 | ChiCTR2000039715 | |||||
| 38 | RNA | RNA based vaccine | LNP-nCoVsaRNA | IM | Imperial College London | Phase 1 | ISRCTN17072692 | ||||||
| 39 | RNA | RNA based vaccine | SARS-CoV-2 mRNA vaccine (ARCoV) | IM | Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences | Phase 1 | ChiCTR2000034112 | ||||||
| ChiCTR2000039212 | |||||||||||||
| 40 | VLP | Virus like particle | Coronavirus-Like Particle COVID-19 (CoVLP) | IM | Medicago Inc. | Phase 2/3 | NCT04662697 | NCT04636697 | |||||
| Study Report | |||||||||||||
| 41 | VVr + APC | Viral vector (Replicating) + APC | Covid-19/aAPC vaccine. The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune modulatory genes and the viral minigenes to the artificial antigen presenting cells (aAPCs). | SC | Shenzhen Geno-Immune Medical Institute | Phase 1 | NCT04299724 | ||||||
| 42 | VVnr + APC | Viral vector (Non-replicating) + APC | LV-SMENP-DC vaccine. Dendritic cells are modified with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs are activated by LV-DC presenting Covid-19 specific antigens. | SC & IV | Shenzhen Geno-Immune Medical Institute | Phase 1/2 | NCT04276896 | ||||||
| 43 | PS | Protein subunit | AdimrSC-2f (recombinant RBD +/- Aluminium) | ND | Adimmune Corporation | Phase 1 | NCT04522089 | ||||||
| 44 | DNA | DNA based vaccine | Covigenix VAX-001 – DNA vaccines + proteo-lipid vehicle (PLV) formulation | IM | Entos Pharmaceuticals Inc. | Phase 1 | NCT04591184 | ||||||
| 45 | DNA | DNA based vaccine | CORVax – Spike (S) Protein Plasmid DNA Vaccine | ID | Providence Health & Services | Phase 1 | NCT04627675 | ||||||
| 46 | RNA | RNA based vaccine | ChulaCov19 mRNA vaccine | IM | Chulalongkorn University | Phase 1 | NCT04566276 | ||||||
| 47 | DNA | DNA based vaccine | bacTRL-Spike oral DNA vaccine | Oral | Symvivo Corporation | Phase 1 | NCT04334980 | ||||||
| 48 | VVnr | Viral vector (Non-replicating) | Human Adenovirus Type 5: hAd5 S+N vaccine (S-Fusion + N-ETSD). E2b- Deleted Adeno. | SC or Oral | ImmunityBio, Inc. & NantKwest, Inc. | Phase 1 | NCT04591717 | ||||||
| NCT04710303 | |||||||||||||
| NCT04732468 | |||||||||||||
| 49 | VVnr | Viral vector (Non-replicating) | COH04S1 (MVA-SARS-2-S) – Modified vaccinia ankara (sMVA) platform + synthetic SARS-CoV-2 | IM | City of Hope Medical Center + National Cancer Institute | Phase 1 | NCT04639466 | ||||||
| Pre-clinical result | |||||||||||||
| 50 | VVr | Viral vector (Replicating) | rVSV-SARS-CoV-2-S Vaccine | IM | Israel Institute for Biological Research | Phase 1/2 | NCT04608305 | ||||||
| 51 | VVr + APC | Viral vector (Replicating) + APC | Dendritic cell vaccine AV-COVID-19. A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF | IM | Aivita Biomedical, Inc. National Institute of Health Research and Development, Ministry of Health Republic of Indonesia | Phase 1/2 | NCT04690387 | NCT04386252 | |||||
| NCT04685603 | |||||||||||||
| 52 | LAV | Live attenuated virus | COVI-VAC | IN | Codagenix/Serum Institute of India | Phase 1 | NCT04619628 | ||||||
| 53 | PS | Protein subunit | CIGB-669 (RBD+AgnHB) | IN | Center for Genetic Engineering and Biotechnology (CIGB) | Phase 1/2 | RPCEC00000345 | ||||||
| 54 | PS | Protein subunit | CIGB-66 (RBD+aluminium hydroxide) | IM | Center for Genetic Engineering and Biotechnology (CIGB) | Phase 1/2 | RPCEC00000346 | ||||||
| 55 | IV | Inactivated Virus | VLA2001 | IM | Valneva, National Institute for Health Research, United Kingdom | Phase 1/2 | NCT04671017 | ||||||
| 56 | PS | Protein subunit | BECOV2 | IM | Biological E. Limited | Phase 1/2 | CTRI/2020/11/029032 | ||||||
| 57 | VVr | Viral vector (Replicating) | AdCLD-CoV19 (adenovirus vector) | IM | Cellid Co., Ltd. | Phase 1/2 | NCT04666012 | ||||||
| 58 | DNA | DNA based vaccine | GLS-5310 | ID | GeneOne Life Science, Inc. | Phase 1/2 | NCT04673149 | ||||||
| 59 | PS | Protein subunit | Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted | IM | Nanogen Pharmaceutical Biotechnology | Phase 1/2 | NCT04683484 | ||||||
| 60 | PS | Protein subunit | Recombinant protein vaccine S-268019 (using Baculovirus expression vector system) | IM | Shionogi | Phase 1/2 | jRCT2051200092 | ||||||
| Viral vector (Non-replicating) | AdCOVID, Adenovirus-based platform expresses the receptor-binding domain (RBD) of the Sars-Cov-2 spike protein | IN | Altimmune, Inc. | Phase 1 | NCT04679909 | ||||||||
| 61 | VVnr | Viral vector (Non-replicating) | AZD2816; adenoviral vector ChAdOx platform and based on the Beta (B.1.351) variant | IM | AstraZeneca + University of Oxford | Phase 2/3 | NCT04973449 | ||||||
| 62 | PS | Protein subunit | SARS-CoV-2-RBD-Fc fusion protein | SC or IM | University Medical Center Groningen + Akston Biosciences Inc. | Phase 1/2 | NCT04681092 | ||||||
| 63 | IV | Inactivated Virus | ERUCOV-VAC, inactivated virus | IM | Erciyes University | Phase 1 | NCT04691947 | ||||||
| 64 | PS | Protein subunit | COVAC-1 and COVAC-2 sub-unit vaccine (spike protein) + SWE adjuvant | IM | University of Saskatchewan | Phase 1/2 | NCT04702178 | ||||||
| 65 | PS | Protein subunit | GBP510, a recombinant surface protein vaccine with adjuvant AS03 (aluminium hydroxide) | IM | SK Bioscience Co., Ltd. | Phase 1/2 | NCT04742738 | ||||||
| NCT04750343 | |||||||||||||
| 66 | PS | Protein subunit | Razi Cov Pars, recombinant spike protein | IM and IN | Razi Vaccine and Serum Research Institute | Phase 1 | IRCT20201214049709N1 | ||||||
| 67 | IV | Inactivated Virus | COVID-19 inactivated vaccine | IM | Shifa Pharmed Industrial Co | Phase 1 | IRCT20201202049567N1 | ||||||
| 68 | PS | Protein subunit | MF59 adjuvanted SARS-CoV-2 Sclamp vaccine | IM | The University of Queensland | Phase 1 | NCT04495933 | ||||||
| Study Report | |||||||||||||
| 69 | DNA | DNA based vaccine | COVIGEN | ID or IM | University of Sydney, Bionet Co., Ltd Technovalia | Phase 1 | NCT04742842 | ||||||
| 70 | DNA | DNA based vaccine | COVID-eVax, a candidate plasmid DNA vaccine of the Spike protein | IM | Takis + Rottapharm Biotech | Phase 1/2 | EudraCT:2020-003734-20 | ||||||
| 71 | VVnr | Viral vector (Non-replicating) | BBV154, Adenoviral vector COVID-19 vaccine | IN | Bharat Biotech International Limited | Phase 1 | NCT04751682 | ||||||
| 72 | DNA | DNA based vaccine | COVID-eVax, A plasmid DNA vaccine targeted Spike protein production | IM | Takis and Rottapharm Biotech | Phase 1/2 | EUCTR2020-003734-20-IT | ||||||
| 73 | RNA | RNA based vaccine | PTX-COVID19-B, mRNA vaccine | IM | Providence Therapeutics | Phase 1 | NCT04765436 | ||||||
| 74 | VVr | Viral vector (Replicating) | NDV-HXP-S, Newcastle disease virus (NDV) vector expressing the spike protein of SARS-CoV-2, with or without the adjuvant CpG 1018 | IM | Mahidol University; The Government Pharmaceutical Organization (GPO); Icahn School of Medicine at Mount Sinai | Phase 1/2 | NCT04764422 | ||||||
| 75 | RNA | RNA based vaccine | CoV2 SAM (LNP) vaccine. A self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform + Spike antigen | IM | GlaxoSmithKline | Phase 1 | NCT04758962 | ||||||
| 76 | VLP | Virus like particle | VBI-2902a. An enveloped virus-like particle (eVLP) of SARS-CoV-2 spike (S) glycoprotein and aluminum phosphate adjuvant. | IM | VBI Vaccines Inc. | Phase 1/2 | NCT04773665 | ||||||
| 77 | PS | Protein subunit | SK SARS-CoV-2 recombinant protein subunit vaccine (NBP2001) + adjuvanted with alum. | IM | SK Bioscience Co., Ltd. | Phase 1 | NCT04760743 | ||||||
| 78 | VVnr | Viral vector (Non-replicating) | Chimpanzee Adenovirus serotype 68 (ChAd) and self-amplifying mRNA (SAM) vectors expressing spike alone, or spike plus additional SARS-CoV-2 T cell epitopes. | IM | Gritstone Oncology | Phase 1 | NCT04776317 | ||||||
| 79 | RNA | RNA based vaccine | mRNA-1273.351. A lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant. | IM | Moderna + National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | NCT04785144 | ||||||
| 80 | PS | Protein subunit | SpFN (spike ferritin nanoparticle) uses spike proteins with a liposomal formulation QS21 (ALFQ) adjuvant. | IM | Walter Reed Army Institute of Research (WRAIR) | Phase 1 | NCT04784767 | ||||||
| 81 | PS | Protein subunit | EuCorVac-19; A spike protein using the recombinant protein technology and with an adjuvant. | IM | EuBiologics Co.,Ltd | Phase 1/2 | NCT04783311 | ||||||
| 82 | LAV | Live attenuated virus | MV-014-212, a live attenuated vaccine that expresses the spike (S) protein of SARS-CoV-2 | IN | Meissa Vaccines, Inc. | Phase 1 | NCT04798001 | ||||||
| 83 | RNA | RNA based vaccine | MRT5500, an mRNA vaccine candidate | IM | Sanofi Pasteur and Translate Bio | Phase 1/2 | NCT04798027 | ||||||
| 84 | VLP | Virus like particle | SARS-CoV-2 VLP Vaccine | IM | The Scientific and Technological Research Council of Turkey | Phase 1 | NCT04818281 | ||||||
| 85 | PS | Protein subunit | ReCOV: Recombinant two-component spike and RBD protein COVID-19 vaccine (CHO cell). | IM | Jiangsu Rec-Biotechnology | Phase 1 | NCT04818801 | ||||||
| 86 | RNA | RNA based vaccine | DS-5670a, mRNA vaccine | IM | Daiichi Sankyo Co., Ltd. | Phase 1/2 | NCT04821674 | ||||||
| 87 | IV | Inactivated Virus | Inactivated COVID-19 vaccine | IM | Kocak Farma | Phase 1 | NCT04838080 | ||||||
| 88 | VVnr | Viral vector (Non-replicating) | COVIVAC. Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein +/- adjuvant CpG 1018 | IM | Institute of Vaccines and Medical Biologicals Vietnam | Phase 1/2 | NCT04830800 | ||||||
| 89 | VVnr | Viral vector (Non-replicating) | SC-Ad6-1 Adneviral vector vaccine | IM | Tetherex Pharmaceuticals Corporation | Phase 1 | NCT04839042 | ||||||
| 90 | VLP | Virus like particle | ABNCoV2 capsid virus-like particle (cVLP) +/- adjuvant MF59 | IM | Radboud University | Phase 1 | NCT04839146 | ||||||
| 91 | PS | Protein subunit | Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) | IM | Guangdong Provincial Center for Disease Control and Prevention/Gaozhou Center for Disease Control and Prevention | Phase 2 | ChiCTR2100045108 | ChiCTR2100045107 | |||||
| 92 | RNA | RNA based vaccine | HDT-301: Self-replicating mRNA vaccine formulated as a lipid nanoparticle. | IM | SENAI CIMATEC | Phase 1 | NCT04844268 | ||||||
| 93 | IV | Inactivated Virus | Adjuvanted inactivated vaccine against SARS-CoV-2 | SC | The Scientific and Technological Research Council of Turkey (TÜBITAK) | Phase 1 | NCT04866069 | ||||||
| 94 | RNA | RNA based vaccine | mRNA-1283 | IM | ModernaTX, Inc. | Phase 1 | NCT04813796 | ||||||
| 95 | PS | Protein subunit | Recombinant SARS-CoV-2 Vaccine (CHO cell) | IM | National Vaccine and Serum Institute, China | Phase 1/2 | NCT04869592 | ||||||
| 96 | RNA | RNA based vaccine | EXG-5003; a temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein. | ID | Elixirgen Therapeutics, Inc | Phase 1/2 | NCT04863131 | ||||||
| 97 | IV | Inactivated Virus | Inactivated COVID-19 vaccine | IM | Elixirgen Therapeutics, IncKM Biologics Co., Ltd. | Phase 1/2 | jRCT2071200106 | ||||||
| 98 | IV | Inactivated Virus | Live recombinant Newcastle Disease Virus (rNDV) vector vaccine | IM or IN | Laboratorio Avi-Mex | Phase 1 | NCT04871737 | ||||||
| 99 | RNA | RNA based vaccine | mRNA COVID-19 vaccine | IM | Shanghai East Hospital and Stemirna Therapeutics | Phase 1 | ChiCTR2100045984 | ||||||
| 100 | PS | Protein subunit | CoVepiT vaccine: SARS-CoV-2 multi-target peptide vaccine (targeting Spike, M, N, and several non-structural proteins) | SC | OSE Immunotherapeutics | Phase 1 | NCT04885361 | ||||||
| 101 | VVnr | Viral vector (Non-replicating) | Modified Vaccinia Virus Ankara (MVA) vector expressing a stabilized SARS-CoV-2 spike protein | IM | German Center for Infection Research | Phase 1/2 | NCT04895449 | ||||||
| 102 | PS | Protein subunit | CoV2-OGEN1, protein-based vaccine | Oral | VaxForm | Phase 1 | NCT04893512 | ||||||
| 103 | PS | Protein subunit | QazCoVac-P – COVID-19 Subunit Vaccine | IM | Research Institute for Biological Safety Problems | Phase 1/2 | NCT04930003 | ||||||
| 104 | RNA | RNA based vaccine | LNP-nCOV saRNA-02 vaccine; Self-amplifying RNA (saRNA) encapsulated in lipid nanoparticles (LNP) | IM | MRC/UVRI and LSHTM Uganda Research Unit | Phase 1 | NCT04934111 | ||||||
| 105 | RNA | RNA based vaccine | mRNA-1273.211. A multivalent booster candidate combining mRNA-1273 plus mRNA-1273.351. | IM | ModernaTX, Inc. | Phase 2/3 | NCT04927065 | ||||||
| 106 | PS | Protein subunit | RBD protein recombinant SARS-CoV-2 vaccine | IM | Bagheiat-allah University of Medical Sciences | Phase 1 | IRCT20210620051639N1 | ||||||
| 107 | PS | Protein subunit | Baiya SARS-CoV-2 VAX1, a plant-based subunit vaccine(RBD-Fc + adjuvant) | IM | Baiya Phytopharm Co., Ltd. | Phase 1 | NCT04953078 | ||||||
| 108 | PS | Protein subunit | SCB-2020S, an adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from B.1.351 variant) | IM | Clover Biopharmaceuticals AUS Pty Ltd | Phase 2 | NCT04950751 ** | ||||||
| 109 | VVnr | Viral vector (Non-replicating) | PIV5 vector that encodes the SARS-CoV-2 spike protein | IM | CyanVac LLC | Phase 1 | NCT04954287 | ||||||
| 110 | PS | Protein subunit | 202-CoV; SARS-CoV-2 spike trimer protein + adjuvant, CpG7909. | IM | Shanghai Zerun Biotechnology + Walvax Biotechnology + CEPI | Phase 1 | NCT04982068 | NCT04990544 | |||||
| 111 | DNA | DNA based vaccine | AG0302-COVID19 | IM | AnGes, Inc | Phase 1/2 | NCT04993586 | ||||||
| 112 | PS | Protein subunit | Recombinant protein RBD fusion dimer adjuvanted vaccine (COVID-19 Vaccine Hipra) | IM | Laboratorios Hipra, S.A. | Phase 1/2 | NCT05007509 | ||||||
| 113 | PS | Protein subunit | Versamune-CoV-2FC vaccine, recombinant S1 antigen | NR | Hospital do Coracao | Phase 1/2 | NCT05016934 | ||||||
| 114 | RNA | RNA based vaccine | ARCT-154 mRNA Vaccine | IM | Arcturus Therapeutics, Inc. | Phase 2/3 | NCT05037097 | NCT05012943 | |||||
| 115 | NA | PRNA based vaccine | ARCT-165 mRNA Vaccine | IM | Arcturus Therapeutics, Inc. | Phase 1/2 | NCT05037097 | ||||||
| 116 | NA | PRNA based vaccine | ARCT-021 mRNA Vaccine | IM | Arcturus Therapeutics, Inc. | Phase 1/2 | NCT05037097 | ||||||
| 117 | PS | Protein subunit | SII B.1.351 + Matrix-M1 adjuvant, a monovalent SII SARS-CoV-2 B.1.351 (Beta) variant vaccine | IM | Novavax | Phase 1/2 | NCT05029856 | ||||||
| 118 | PS | Protein subunit | SII Bivalent + Matrix-M1 adjuvant, a bivalent SII vaccine containing antigen for both the ancestral strain and B.1.351 (Beta) variant of SARS-CoV-2 | IM | Novavax | Phase 1/2 | NCT05029857 | ||||||
| 119 | PS | Protein subunit | SII B.1.617.2 + Matrix-M1 adjuvant, a monovalent SII SARS-CoV-2 B.1.617.2 (Delta) variant vaccine | IM | Novavax | Phase 1/2 | NCT05029858 | ||||||
| 120 | VVnr | Viral vector (Non-replicating) | AAV5-RBD-S vaccine (BCD-250), A recombinant Adenovirus-Associated viral Vector (AAV-5) encoding spike protein | IM | Biocad | Phase 1/2 | NCT05037188 | ||||||
| 121 | PS | Protein subunit | SCTV01C. A Bivalent Recombinant Trimeric S Protein vaccine against SARS-CoV-2 Variants | IM | Sinocelltech Ltd. | Phase 2/3 | NCT05043311 | ||||||
| 122 | IV | Inactivated Virus | Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) | IM | Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products | Phase 1/2 | NCT05046548 | ||||||
| 123 | DNA | DNA based vaccine | Plasmid DNA vaccine SCOV1 + SCOV2. COVIDITY | ID/IM | Scancell Ltd | Phase 1 | NCT04982068 | ||||||
| 124 | BacAg-SpV | Bacterial antigen-spore expression vector | COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores | Oral | DreamTec Research Limited | NA | |||||||
| 125 | DNA | DNA based vaccine | VB10.2129, a DNA plasmid vaccine, encoding the receptor binding domain (RBD) | IM | Vaccibody AS | Phase 1/2 | NCT05069623 | ||||||
| 126 | DNA | DNA based vaccine | VB10.2210, DNA plasmid vaccine, encodes multiple immunogenic and conserved T cellepitopes spanning multiple antigens across the SARS-CoV-2 genome. | IM | Vaccibody AS | Phase 1/2 | NCT05069623 | ||||||
| 127 | ps | Protein subunit | SARS-CoV-2 Protein Subunit Recombinant Vaccine | IM | Bio Farma | Phase 1/2 | NCT05067894 | ||||||
| 128 | PS | Protein subunit | PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine | IM | Yisheng Biopharma | Phase 1 | ACTRN12621001009808 | ||||||
| 129 | DNA | DNA based vaccine | SARS-CoV-2 DNA vaccine (delivered IM followed by electroporation) | IM | The University of Hong Kong; Immuno Cure 3 Limited | Phase 1 | NCT05102643 | ||||||
| 131 | VVnr | Viral vector (Non-replicating) | Ad5-triCoV/Mac or ChAd-triCoV/Mac, new experimental adenovirus-based vaccines expressing SARS-CoV-2 spike, nucleocapsid and RNA polymerase proteins | AE | McMaster University | Phase 1 | NCT05094609 | ||||||
| 132 | PS | Protein subunit | PepGNP-SARSCoV2, A CD8 T-cell priming adaptive vaccine composed of a Coronaviruses specific peptides mounted on a gold nanoparticle | ID | Emergex Vaccines Holding Limited | Phase 1 | NCT05113862 | ||||||
| 133 | PS | Protein subunit | SARS-CoV-2 Vaccine (IN-B009) | IM | HK inno.N Corporation | Phase 1 | NCT05113849 | ||||||
| 134 | VLP | Virus like particle | SARS-CoV-2 Vaccine LYB001, a receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide. | IM | Yantai Patronus Biotech Co., Ltd. | Phase 1 | NCT05125926 | NCT05137444 | |||||
| 135 | IV | Inactivated Virus | Covi Vax, inactivated coronavirus vaccine | IM | National Research Centre, Egypt | Phase 1 | NCT05128721 | ||||||
| 136 | RNA | RNA based vaccine | HDT-301 vaccine | IM | HDT Bio | Phase 1 | NCT05132907 | ||||||
| 137 | RNA | RNA based vaccine | VLPCOV-01, self-amplifying RNA vaccine against the coronavirus | IM | VLP Therapeutics Japan GK | Phase 1 | jRCT2071210067 | ||||||
194 candidate vaccines in preclinical evaluation
| ID | Vaccine platform acronym | Vaccine platform description | Type of candidate vaccine | Coronavirus target | Same platform for non-Coronavirus candidates | Developers |
| 1 | DNA | DNA based vaccine | DNA, engineered vaccine inserts compatible with multiple delivery systems | SARS-CoV-2 and Sarbeco-CoV | DIOSynVax Ltd + University of Cambridge | |
| 2 | DNA | DNA based vaccine | DNA vaccine | SARS-CoV2 | Ege University | |
| 3 | DNA | DNA based vaccine | DNA plasmid vaccine RBD&N | SARS-CoV2 | Scancell/University of Nottingham/ Nottingham Trent University | |
| 4 | DNA | DNA based vaccine | DNA with electroporation | SARS-CoV2 | Karolinska Institute / Cobra Biologics (OPENCORONA Project) | |
| 5 | DNA | DNA based vaccine | DNA with electroporation | SARS-CoV2 | Chula Vaccine Research Center | |
| 6 | DNA | DNA based vaccine | Plasmid DNA, Needle-Free Delivery | SARS-CoV2 | SARS | Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet |
| 7 | DNA | DNA based vaccine | DNA plasmid vaccine S,S1,S2,RBD &N | SARS-CoV2 | National Research Centre, Egypt | |
| 8 | DNA | DNA based vaccine | DNA vaccine | SARS-CoV2 | BioNet Asia | |
| 9 | DNA | DNA based vaccine | msDNA vaccine | SARS-CoV2 | Mediphage Bioceuticals/University of Waterloo | |
| 10 | DNA | DNA based vaccine | DNA vaccine | SARS-CoV2 | Entos Pharmaceuticals | |
| 11 | DNA | DNA based vaccine | DNA plasmids containing S-gene | SARS-CoV2 | Biosun Pharmed | |
| 12 | DNA | DNA based vaccine | DNA plasmid vaccine | SARS-CoV2 | Globe Biotech Limited, Bangladesh | |
| 13 | DNA | DNA based vaccine | Plasmid DNA, nanostructured RBD | SARS-CoV2 | National institute of Chemistry, Slovenia | |
| 14 | DNA | DNA based vaccine | DNA plasmid vaccine encoding RBD | SARS-CoV2 | Vaccibody, Oslo Research Park, Norway | |
| 15 | DNA | DNA based vaccine | DNA Immunostimulatory sequences | SARS-CoV2 | Inserm | |
| 16 | DNA | DNA based vaccine | The 3 regions of SARS-Cov-2 Spike-protein: NTD, RBD and HR1-HR2 inserted into the plasmid of PcDNA3.1 (+). | SARS-CoV2 | Center of Genomics and Bioinformatics of Academy of Science of Republic of Uzbekistan | |
| 17 | IV | Inactivated virus | Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018 | SARS-CoV-2 | Institute Butantan (Brazil) / Dynavax / PATH | |
| 18 | IV | Inactivated virus | Inactivated + alum | SARS-CoV2 | JE, Zika | KM Biologics |
| 19 | IV | Inactivated virus | Inactivated | SARS-CoV2 | Selcuk University | |
| 20 | IV | Inactivated virus | SARS-CoV2 | Osaka University/ BIKEN/ NIBIOHN | ||
| 21 | IV | Inactivated virus | Inactivated + CpG 1018 | SARS-CoV2 | Sinovac/Dynavax | |
| 22 | IV | Inactivated virus | Inactivated + CpG 1018 | SARS-CoV2 | Valneva/Dynavax | |
| 23 | IV | Inactivated virus | Inactivated whole virus | SARS-CoV2 | National Research Centre, Egypt | |
| 24 | IV | Inactivated virus | Inactivated | SARS-CoV2 | MMR, IPV | Milad Pharmaceutics Co. |
| 25 | IV | Inactivated virus | Inactivated | SARS-CoV2 | MMR, IPV | Zista Kian Azma Co. |
| 26 | IV | Inactivated virus | Inactivated + alum | SARS-CoV2 | Paya Fan Yakhte Alborz – Osveh / Iran | |
| 27 | IV | Inactivated virus | Inactivated vaccine (Vero Cell) | SARS-CoV2 | Airlangga University, Indonesia in partnership with Biotis Pharmaceuticals Indonesia | |
| 28 | LAV | Live attenuated virus | Codon deoptimized live attenuated vaccines | SARS-CoV2 | Mehmet Ali Aydinlar University / Acıbadem Labmed Health Services A.S. | |
| 29 | LAV | Live attenuated virus | Codon deoptimized live attenuated vaccines | SARS-CoV2 | Indian Immunologicals Ltd/Griffith University | |
| 30 | LABV | Live attenuated bacterial vector | Live attenuated bacterial (Pertussis) Vector | SARS-CoV2 | Institut Pasteur Lille, Inserm | |
| 31 | LABV | Live attenuated bacterial vector | Live attenuated bacterial vector | SARS-CoV2 | ALtraBio, TheRex | |
| 32 | VVnr | Viral vector (Non-replicating) | Sendai virus vector | SARS-CoV2 | ID Pharma | |
| 33 | VVnr | Viral vector (Non-replicating) | Sendai virus vector | SARS-CoV2 | RSV, CMV | Max Planck Institute for Biochemstry/vir4vac, Germany |
| 34 | VVnr | Viral vector (Non-replicating) | Adenovirus-based | SARS-CoV2 | Ankara University | |
| 35 | VVnr | Viral vector (Non-replicating) | Adeno-associated virus vector (AAVCOVID) | SARS-CoV2 | Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis | |
| 36 | VVnr | Viral vector (Non-replicating) | MVA encoded VLP | SARS-CoV2 | LASV, EBOV, MARV, HIV | GeoVax/BravoVax |
| 37 | VVnr | Viral vector (Non-replicating) | MVA-S | SARS-CoV2 | IDIBAPS-Hospital Clinic, Spain | |
| 38 | VVnr | Viral vector (Non-replicating) | Adeno5-based | SARS-CoV2 | Erciyes University | |
| 39 | VVnr | Viral vector (Non-replicating) | Ad5 S (GREVAX™ platform) | SARS-CoV2 | MERS | Greffex |
| 40 | VVnr | Viral vector (Non-replicating) | Oral Ad5 S | SARS-CoV2 | Zika, VZV, HSV-2 and Norovirus | Stabilitech Biopharma Ltd |
| 41 | VVnr | Viral vector (Non-replicating) | Adenovirus-based + HLA-matched peptides | Pan-Corona | Valo Therapeutics Ltd | |
| 42 | VVnr | Viral vector (Non-replicating) | MVA expressing structural proteins | SARS-CoV2 | Multiple candidates | Centro Nacional Biotecnología (CNB-CSIC), Spain |
| 43 | VVnr | Viral vector (Non-replicating) | Parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein | SARS-CoV2 | MERS | University of Georgia/University of Iowa |
| 44 | VVnr | Viral vector (Non-replicating) | Recombinant deactivated rabies virus containing S1 | SARS-CoV2 | HeV, NiV, EBOV, LASSA, CCHFV, MERS | Bharat Biotech/Thomas Jefferson University |
| 45 | VVnr | Viral vector (Non-replicating) | Influenza A H1N1 vector | SARS-CoV2 | National Research Centre, Egypt | |
| 46 | VVnr | Viral vector (Non-replicating) | Newcastle disease virus expressing the spike protein | SARS-CoV2 | Icahn School of Medicine at Mount Sinai | |
| 47 | VVnr | Viral vector (Non-replicating) | Newcastle disease virus expressing membrane-anchored spike | SARS-CoV2 | Icahn School of Medicine at Mount Sinai | |
| 48 | VVnr | Viral vector (Non-replicating) | Lentiviral Vector | SARS-CoV2 | Theravectys – Institut Pasteur | |
| 49 | VVnr | Viral vector (Non-replicating) | Lentiviral Vector | SARS-CoV2 | AIOVA | |
| 50 | VVnr | Viral vector (Non-replicating) | Lentiviral Vector Retro-VLP Particles | SARS-CoV2 | Sorbonne University | |
| 51 | VVnr | Viral vector (Non-replicating) | Ad 5 vector for intranasal administration | SARS-CoV2 | University of Helsinki & University of Eastern Finland | |
| 52 | VVnr | Viral vector (Non-replicating) | Oral vaccine platform | SARS-CoV2 | InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE | Vaxart |
| 53 | VVnr | Viral vector (Non-replicating) | Recombinant Adenovirus Vector (Type 5) + Spike protein of SARS-CoV-2 | SARS-CoV2 | Pasteur Institute / Iran | |
| 54 | VVnr | Viral vector (Non-replicating) | Recombinant Adenovirus Vector (ChAdOx1) + Spike protein of SARS-CoV-2 | SARS-CoV2 | Pasteur Institute / Iran | |
| 55 | VVnr | Viral vector (Non-replicating) | Adenovirus-based | SARS-CoV2 | Home Iman Zist Fanavar | |
| 56 | VVnr | Viral vector (Non-replicating) | Chimpanzee adenovirus vector expressing the RBD-dimer without adjuvant | SARS-CoV2 | Chengdu Kanghua Biological Products Co., Ltd. | |
| 57 | PS | Protein subunit | RBD protein delivered in mannose-conjugated chitosan nanoparticle | SARS-CoV2 | Ohio State University / Kazakh National Agrarian University | |
| 58 | PS | Protein subunit | Recombinant spike protein with Essai O/W 1849101 adjuvant | SARS-CoV2 | Kazakh National Agrarian University | |
| 59 | PS | Protein subunit | Peptides | SARS-CoV2 | Neo7Logic | |
| 60 | PS | Protein subunit | Recombinant spike protein with Essai O/W 1849101 adjuvant | SARS-CoV2 | Kazakh National Agrarian University, Kazakhstan / National Scientific Center for Especially Dangerous Infections | |
| 61 | PS | Protein subunit | Recombinant S protein | SARS-CoV2 | Max-Planck-Institute of Colloids and Interfaces | |
| 62 | PS | Protein subunit | RBD protein (baculovirus production) + FAR-Squalene adjuvant | SARS-CoV2 | Multiple candidates | Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH) |
| 63 | PS | Protein subunit | RBD-protein | SARS-CoV2 | Mynvax | |
| 64 | PS | Protein subunit | Recombinant S protein | SARS-CoV2 | Izmir Biomedicine and Genome Center | |
| 65 | PS | Protein subunit | Peptide + novel adjuvant | SARS-CoV2 | Bogazici University | |
| 66 | PS | Protein subunit | S subunit intranasal liposomal formulation with GLA/3M052 adjs. | SARS-CoV2 | University of Virginia | |
| 67 | PS | Protein subunit | S-Protein (Subunit) + Adjuvant, E coli and Insect vectors for expression/synthesis of the protein | SARS-CoV2 | Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria. | |
| 68 | PS | Protein subunit | Protein Subunit S,N,M&S1 protein | SARS-CoV2 | National Research Centre, Egypt | |
| 69 | PS | Protein subunit | Protein Subunit | SARS-CoV2 | University of San Martin and CONICET, Argentina | |
| 70 | PS | Protein subunit | RBD protein fused with Fc of IgG + Adj. | SARS-CoV2 | Chulalongkorn University/GPO, Thailand | |
| 71 | PS | Protein subunit | Capsid-like Particle | SARS-CoV2 | AdaptVac (PREVENT-nCoV consortium) | |
| 72 | PS | Protein subunit | Drosophila S2 insect cell expression system VLPs | SARS-CoV2 | ExpreS2ion | |
| 73 | PS | Protein subunit | Peptide antigens formulated in LNP | SARS-CoV2 | IMV Inc | |
| 74 | PS | Protein subunit | S protein | SARS-CoV2 | WRAIR/USAMRIID | |
| 75 | PS | Protein subunit | S protein +Adjuvant | SARS-CoV2 | Influenza | National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma |
| 76 | PS | Protein subunit | VLP-recombinant protein + Adjuvant | SARS-CoV2 | Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan | |
| 77 | PS | Protein subunit | microneedle arrays S1 subunit | SARS-CoV2 | MERS | Univ. of Pittsburgh |
| 78 | PS | Protein subunit | Peptide | SARS-CoV2 | Vaxil Bio | |
| 79 | PS | Protein subunit | Adjuvanted protein subunit (RBD) | SARS-CoV2 | Biological E Ltd | |
| 80 | PS | Protein subunit | Peptide | SARS-CoV2 | Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA vaccine | Flow Pharma Inc |
| 81 | PS | Protein subunit | S protein | SARS-CoV2 | AJ Vaccines | |
| 82 | PS | Protein subunit | Ii-Key peptide | SARS-CoV2 | Influenza, HIV, SARS-CoV | Generex/EpiVax |
| 83 | PS | Protein subunit | S protein | SARS-CoV2 | H7N9 | EpiVax/Univ. of Georgia |
| 84 | PS | Protein subunit | Protein Subunit EPV-CoV-19 | SARS-CoV2 | EpiVax | |
| 85 | PS | Protein subunit | gp-96 backbone | SARS-CoV2 | NSCLC, HIV, Malaria, Zika | Heat Biologics/Univ. Of Miami |
| 86 | PS | Protein subunit | Subunit vaccine | SARS-CoV2 | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | |
| 87 | PS | Protein subunit | S1 or RBD protein | SARS-CoV2 | SARS | Baylor College of Medicine |
| 88 | PS | Protein subunit | Subunit protein, plant produced | SARS-CoV2 | iBio/CC-Pharming | |
| 89 | PS | Protein subunit | Recombinant protein, nanoparticles (based on S-protein and other epitopes) | SARS-CoV2 | Saint-Petersburg scientific research institute of vaccines and serums | |
| 90 | PS | Protein subunit | Cross-reactive T-cell recombinant vaccine based on SARS-CoV-2 nucleoprotein (N) expressed in E.coli | SARS-CoV2 | various (cross-immunity) | FSUE SPbSRIVS FMBA of Russia (St. Petersburg Institute of Vaccines) |
| 91 | PS | Protein subunit | COVID-19 XWG-03 truncated S (spike) proteins | SARS-CoV2 | HPV | Innovax/Xiamen Univ./GSK |
| 92 | PS | Protein subunit | Adjuvanted microsphere peptide | SARS-CoV2 | VIDO-InterVac, University of Saskatchewan | |
| 93 | PS | Protein subunit | Synthetic Long Peptide Vaccine candidate for S and M proteins | SARS-CoV2 | OncoGen | |
| 94 | PS | Protein subunit | Oral E. coli-based protein expression system of S and N proteins | SARS-CoV2 | MIGAL Galilee Research Institute | |
| 95 | PS | Protein subunit | Nanoparticle vaccine | SARS-CoV2 | LakePharma, Inc. | |
| 96 | PS | Protein subunit | Plant-based subunit (RBD-Fc + Adjuvant) | SARS-CoV2 | Baiya Phytopharm/ Chula Vaccine Research Center | |
| 97 | PS | Protein subunit | OMV-based vaccine | SARS-CoV2 | Flu A, Plague | Quadram Institute Biosciences |
| 98 | PS | Protein subunit | OMV-based vaccine | SARS-CoV2 | BiOMViS Srl/Univ. of Trento | |
| 99 | PS | Protein subunit | structurally modified spherical particles of the tobacco mosaic virus (TMV) | SARS-CoV2 | Rubella, Rotavirus | Lomonosov Moscow State University |
| 100 | PS | Protein subunit | Spike-based | SARS-CoV2 | Hepatitis C | University of Alberta |
| 101 | PS | Protein subunit | Recombinant S1-Fc fusion protein | SARS-CoV2 | AnyGo Technology | |
| 102 | PS | Protein subunit | Recombinant protein | SARS-CoV2 | Yisheng Biopharma | |
| 103 | PS | Protein subunit | Recombinant S protein in IC-BEVS (Viral vector vaccine (based on baculovirus expression system in insect cell line) | SARS-CoV2 | Vabiotech, Vietnam and University of Bristol, UK | |
| 104 | PS | Protein subunit | Orally delivered, heat stable subunit | SARS-CoV2 | Applied Biotechnology Institute, Inc. | |
| 105 | PS | Protein subunit | Peptides derived from Spike protein | SARS-CoV2 | Axon Neuroscience SE | |
| 106 | PS | Protein subunit | Protein Subunit | SARS-CoV2 | MOGAM Institute for Biomedical Research, GC Pharma | |
| 107 | PS | Protein subunit | RBD-based | SARS-CoV2 | Neovii/Tel Aviv University | |
| 108 | PS | Protein subunit | Outer Membrane Vesicle (OMV)-subunit | SARS-CoV2 | Intravacc/Epivax | |
| 109 | PS | Protein subunit | Spike-based (epitope screening) | SARS-CoV2 | ImmunoPrecise/LiteVax BV | |
| 110 | PS | Protein subunit | Spiked-based | SARS-CoV2 | Nanografi Nano Technology, Middle East Technical University, Ankara University, | |
| 111 | PS | Protein subunit | Recombinant spike with adjuvant | SARS-CoV2 | Iran | |
| 112 | PS | Protein subunit | Recombinant S protein produced in BEVS | SARS-CoV2 | Tampere University | |
| 113 | PS | Protein subunit | Protein Subunit Nanoformulated | SARS-CoV2 | Vaxinano, CEA, INRAE | |
| 114 | PS | Protein subunit | Protein Subunit Adenoviral Carrier | SARS-CoV2 | CEA, CNRS | |
| 115 | PS | Protein subunit | Protein DC-targeted epitopes | SARS-CoV2 | LinkinVax, VRI, Inserm | |
| 116 | PS | Protein subunit | Soluble recombinant S protein produced in CHO cells | SARS-CoV2 | Center for Advanced Technologies, Uzbekistan | |
| 117 | PS | Protein subunit | NYVAC-KC, attenuated vaccinia virus vector expressing SARS-CoV-2 Spike and other viral proteins | SARS-CoV2 | Arizona State University | |
| 118 | PS | Protein subunit | Protein peptides with alum | SARS-CoV2 | Hacettepe University, Turkey | |
| 119 | PS | Protein subunit | Recombinant Spike (S) proteins encoded by Baculoviruses in Insect cells | SARS-CoV2 | Marmara University, Turkey | |
| 120 | PS | Protein subunit | Adjuvanted Peptides + Recombinant Spike Protein | SARS-CoV2 | Yıldız Technical University, Turkey | |
| 121 | PS | Protein subunit | Development of recombinant protein based S1 and S2 (Spike) and nucleocapsid subunits vaccines using a plant expression vector. | SARS-CoV2 | Akdeniz University, Department of Agricultural Biotechnology, Antalya, Turkey | |
| 122 | PS | Protein subunit | Recombinant Protein Vaccine | SARS-CoV2 | Ataturk University, Vaccine Research Center (Erzurum) and Health Institutes of Turkey (TUSEB) | |
| 123 | PS | Protein subunit | Recombinant protein subunit vaccine | SARS-CoV2 | Pharmada Pharmaceuticals/TURKEY | |
| 124 | PS | Protein subunit | Recombinant Spike Protein | SARS-CoV2 | CinnaGen Co | |
| 125 | PS | Protein subunit | Recombinant SARS CoV-2 RBD Protein, Alum adjuvanted | SARS-CoV2 | Bio Farma + Baylor College Medicine | |
| 126 | PS | Protein subunit | TerraCoV2 recombinant protein (stabilized pre-fusion spike protein) | Wuhan B.1.351 (Beta) | Oragenics Inc, in cooperation with NRC Canada and Biodextris, Inc | |
| 127 | PS | Protein subunit | Multiple peptides fragments targeting (S, M, N) and (NSPs) SARS-CoV-2 proteins to induce T cell responses (CD8) | SARS-CoV2 | OSE immunotherapeutics | |
| 128 | PS | Protein subunit | BD-COV-001 B.1.351 antigen encapsulated in polymersomes | SARS-CoV2 | ACM Biosciences | |
| 129 | PS | Protein subunit | Recombinant protein | SARS-CoV2 | Biosun Pharmed / Iran | |
| 130 | PS | Protein subunit | Recombinant protein with hepatitis B VLP vector + Alum | SARS-CoV3 | Rahpouyan Fanavar Sadegh (RFS) / Iran | |
| 131 | PS | Protein subunit | Recombinant Protein (Leishmania host) | SARS-CoV4 | Zist Salak / Iran | |
| 132 | BVr | Bacterial vector (Replicating) | Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD | SARS-CoV2 | Multiple candidates | Farmacológicos Veterinarios SAC (FARVET SAC) |
| 133 | VVr | Viral vector (Replicating) | YF17D Vector | SARS-CoV2 | KU Leuven | |
| 134 | VVr | Viral vector (Replicating) | Measles Vector | SARS-CoV2 | Cadila Healthcare Limited | |
| 135 | VVr | Viral vector (Replicating) | Measles Vector | SARS-CoV2 | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | |
| 136 | VVr | Viral vector (Replicating) | Measles Virus (S, N targets) | SARS-CoV2 | Zika, H7N9, CHIKV | DZIF – German Center for Infection Research/CanVirex AG |
| 137 | VVr | Viral vector (Replicating) | Horsepox vector expressing S protein | SARS-CoV2 | Smallpox, Monkeypox | Tonix Pharma/Southern Research |
| 138 | VVr | Viral vector (Replicating) | Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal) | SARS-CoV2 | Influenza | BiOCAD and IEM |
| 139 | VVr | Viral vector (Replicating) | Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal) | SARS-CoV2 | Influenza | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo |
| 140 | VVr | Viral vector (Replicating) | Attenuated Influenza expressing an antigenic portion of the Spike protein | SARS-CoV2 | Influenza | Fundação Oswaldo Cruz and Instituto Buntantan |
| 141 | VVr | Viral vector (Replicating) | Influenza vector expressing RBD | SARS-CoV2 | University of Hong Kong | |
| 142 | VVr | Viral vector (Replicating) | Replication-competent VSV chimeric virus technology (VSVΔG) delivering the SARS-CoV-2 Spike (S) glycoprotein. | SARS-CoV2 | Ebola, Marburg, Lassa | IAVI/Merck |
| 143 | VVr | Viral vector (Replicating) | Replicating VSV vector-based DC-targeting | SARS-CoV2 | University of Manitoba | |
| 144 | VVr | Viral vector (Replicating) | VSV-S | SARS-CoV2 | HIV, MERS | University of Western Ontario |
| 145 | VVr | Viral vector (Replicating) | VSV-S | SARS-CoV2 | Aurobindo | |
| 146 | VVr | Viral vector (Replicating) | VSV vector | SARS-CoV2 | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | |
| 147 | VVr | Viral vector (Replicating) | M2-deficient single replication (M2SR) influenza vector | SARS-CoV2 | Influenza | UW–Madison/FluGen/Bharat Biotech |
| 148 | VVr | Viral vector (Replicating) | Newcastle disease virus vector (NDV-SARS-CoV-2/Spike) | SARS-CoV2 | Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ. | |
| 149 | VVr | Viral vector (Replicating) | Avian paramyxovirus vector (APMV) | SARS-CoV2 | The Lancaster University, UK | |
| 150 | VVr | Viral vector (Replicating) | Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing RBD protein: rNDV-LS1-HN-RBD/SARS-CoV-2 | SARS-CoV2 | Multiple candidates | Farmacológicos Veterinarios SAC (FARVET SAC) |
| 151 | VVr | Viral vector (Replicating) | Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing S1 protein: rNDV-LS1-S1-F/SARS-CoV-2 | SARS-CoV2 | Multiple candidates | Farmacológicos Veterinarios SAC (FARVET SAC) |
| 152 | RNA | RNA based vaccine | saRNA formulated in a NLC | SARS-CoV2 | Infectious Disease Research Institute/ Amyris, Inc. | |
| 153 | RNA | RNA based vaccine | LNP-encapsulated mRNA encoding S | SARS-CoV2 | Max-Planck-Institute of Colloids and Interfaces | |
| 154 | RNA | RNA based vaccine | Self-amplifying RNA | SARS-CoV2 | Gennova | |
| 155 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | Selcuk University | |
| 156 | RNA | RNA based vaccine | LNP-mRNA | SARS-CoV2 | Translate Bio/Sanofi Pasteur | |
| 157 | RNA | RNA based vaccine | LNP-mRNA | SARS-CoV2 | CanSino Biologics/Precision NanoSystems | |
| 158 | RNA | RNA based vaccine | LNP-encapsulated mRNA cocktail encoding VLP | SARS-CoV2 | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma | |
| 159 | RNA | RNA based vaccine | LNP-encapsulated mRNA encoding RBD | SARS-CoV2 | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma | |
| 160 | RNA | RNA based vaccine | Replicating Defective SARS-CoV-2 derived RNAs | SARS-CoV2 | Centro Nacional Biotecnología (CNB-CSIC), Spain | |
| 161 | RNA | RNA based vaccine | LNP-encapsulated mRNA | SARS-CoV2 | MERS | University of Tokyo/ Daiichi-Sankyo |
| 162 | RNA | RNA based vaccine | Liposome-encapsulated mRNA | SARS-CoV2 | BIOCAD | |
| 163 | RNA | RNA based vaccine | Several mRNA candidates | SARS-CoV2 | RNAimmune, Inc. | |
| 164 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | |
| 165 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | China CDC/Tongji University/Stermina | |
| 166 | RNA | RNA based vaccine | mRNA in an intranasal delivery system | SARS-CoV2 | eTheRNA | |
| 167 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | Greenlight Biosciences | |
| 168 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | IDIBAPS-Hospital Clinic, Spain | |
| 169 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | Providence Therapeutics | |
| 170 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | Cell Tech Pharmed | |
| 171 | RNA | RNA based vaccine | mRNA | SARS-CoV2 | ReNAP Co. | |
| 172 | RNA | RNA based vaccine | D614G variant LNP-encapsulated mRNA | SARS-CoV2 | Globe Biotech Ltd | |
| 173 | RNA | RNA based vaccine | Encapsulated mRNA | SARS-CoV2 | CEA | |
| 174 | RNA | RNA based vaccine | Recombinant, prefusion stabilized SARS-CoV-2 Spike antigen | SARS-CoV2 | Medigen Vaccines Biologics Corp (MVC)/Vaxess Technologies (MIMIX) | |
| 175 | RNA | RNA based vaccine | ZIP1642 is a self-amplifying RNA vaccine encapsulated in an LNP, which encodes for multiple antigens, including the Spike (S) protein. | SARS-CoV2 | Ziphius Vaccines and Ghent University | |
| 176 | VLP | Virus like particle | VLP | SARS-CoV2 | Max Planck Institute for Dynamics of Complex Technical Systems | |
| 177 | VLP | Virus like particle | Virus-like particle-based Dendritic Cell(DC)-targeting vaccine | SARS-CoV2 | University of Manitoba | |
| 178 | VLP | Virus like particle | VLP | SARS-CoV2 | Bezmialem Vakif University | |
| 179 | VLP | Virus like particle | Enveloped Virus-Like Particle (eVLP) | SARS-CoV-2, SARS-CoV, & MERS-CoV | CMV, GBM, Zika | VBI Vaccines Inc. |
| 180 | VLP | Virus like particle | S protein integrated in HIV VLPs | SARS-CoV2 | IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing Centre/Grifols | |
| 181 | VLP | Virus like particle | VLP + Adjuvant | SARS-CoV2 | Mahidol University/ The Government Pharmaceutical Organization (GPO)/Siriraj Hospital | |
| 182 | VLP | Virus like particle | Virus-like particles, lentivirus and baculovirus vehicles | SARS-CoV2 | Navarrabiomed, Oncoimmunology group | |
| 183 | VLP | Virus like particle | Virus-like particle, based on RBD displayed on virus-like particles | SARS-CoV2 | Saiba GmbH | |
| 184 | VLP | Virus like particle | ADDomerTM multiepitope display | SARS-CoV2 | Imophoron Ltd and Bristol University’s Max Planck Centre | |
| 185 | VLP | Virus like particle | Unknown | SARS-CoV2 | Doherty Institute | |
| 186 | VLP | Virus like particle | VLP | SARS-CoV1, SARS-CoV2 | OSIVAX | |
| 187 | VLP | Virus like particle | eVLP | SARS-CoV2 | Malaria | ARTES Biotechnology |
| 188 | VLP | Virus like particle | VLPs peptides/whole virus | SARS-CoV2 | Univ. of Sao Paulo | |
| 189 | VLP | Virus like particle | VLPs produced in BEVS | SARS-CoV2 | Tampere University | |
| 190 | VLP | Virus like particle | Plant derived VLP | SARS-CoV2 | Shiraz University | |
| 191 | VLP | Virus like particle | Myxoma virus co-expressing S, M, N and E proteins | SARS-CoV2 | Arizona State University | |
| 192 | VLP | Virus like particle | Plasmid driven production of virus -Like-Particles (VLPs) containing S, M, N and E proteins of SARS-CoV-2 | SARS-CoV2 | Arizona State University | |
| 193 | VLP | Virus like particle | Virus Like Particle with RCB | SARS-CoV2 | Berna Biotech Pharma | |
| 194 | Cell | Cellular based vaccine | Engineered human mesenchymal stem cells transfected with a plasmid expressing S and N-protein | SARS-CoV2 | Cell Tech Pharmed |
